Eli Lilly has become the market leader for GLP-1 medications, surpassing Novo Nordisk. The company’s reliance on its GLP-1 drugs is increasing. Sales of their GLP-1 drugs, Mounjaro and Zepbound, have risen significantly, with a 54% increase in overall sales. However, competition from Pfizer in the GLP-1 market poses a threat to Eli Lilly’s dominance. In 10 years, their patent protection on Mounjaro and Zepbound will expire, leading to potential revenue decline. This could impact their current position as a leader in the pharmaceutical sector. Investors are advised to tread with caution due to the impending challenges Eli Lilly may face in the future.

Read more at Yahoo Finance: Where Will Eli Lilly Be in 10 Years?